Opendata, web and dolomites

DrugSynergy SIGNED

DrugSynergy: A data-driven systems biology approach to optimize drug combination strategies

Total Cost €


EC-Contrib. €






Project "DrugSynergy" data sheet

The following table provides information about the project.


Organization address
address: rue d'Ulm 26
city: PARIS
postcode: 75231

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Total cost 150˙000 €
 EC max contribution 150˙000 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2015-PoC
 Funding Scheme ERC-POC
 Starting year 2016
 Duration (year-month-day) from 2016-09-01   to  2018-02-28


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    INSTITUT CURIE FR (PARIS) coordinator 150˙000.00


 Project objective

The complex physiopathology of human chronic diseases includes networks robustness, feedback loops, and cross-talks, which may induce limited efficacy, resistance, and/or excessive toxicity of an individual drug. Learning how to combine drugs in order to improve treatment efficacy and lower undesired toxicity is a major biomedical challenge. Current strategies for drug repositioning and optimization of drug combinations have two man limitations: 1) they mostly use public data and databases, which are based on knowledge of individual drug stimuli and do not specifically analyze interactions, 2) they consider limited number of cellular outputs to analyze the response to a drug. In DrugSynergy, we will use an innovative systems biology large-scale data-driven approach to determine the interaction between two drugs at the highest possible resolution. Our computational analysis workflow has been extensively validated over the past years. It is now robust enough to be applied for the optimization of drug combinations. Our business development strategies will follow several possible non-exclusive scenarios: 1) service providing to pharmaceutical and biotech companies to optimize their own pipeline of drug combinations, 2) generate intellectual property (IP) through identification of new drug combinations, optimization of existing drug combinations by addition of innovative drugs through screening of small molecule libraries, including from our Institute. These goals will be achieved in an academic structure, through licensing new IP to industrial partners, or within a start-up company created around the innovative pipelines and know-how of DrugSynergy. These options will be explored with our business development and industrial partnership department. DrugSynergy is expected to have a strong biomedical and socio-economic impact because of the growing need of efficiently combine multiple drugs to address health challenges such as cancer and chronic inflammatory diseases.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "DRUGSYNERGY" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "DRUGSYNERGY" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)


The Enemy of the Good: Towards a Theory of Moral Progress

Read More  


The Mass Politics of Disintegration

Read More  

FICOMOL (2019)

Field Control of Cold Molecular Collisions

Read More